Navigation Links
Emdeon Recommends Secure Interim Solutions to Avert Delays in the Implementation of ePrescribing of Controlled Substances

NASHVILLE, Tenn., May 27 /PRNewswire-FirstCall/ -- Emdeon Inc. (NYSE: EM), a leading provider of healthcare revenue and payment cycle management solutions, today submitted formal comments to the U.S. Drug Enforcement Administration (DEA) in response to the agency's request for comments on the Interim Final Rule enabling electronic prescribing (ePrescribing) of controlled substances. Emdeon's comments reiterate its support for the proposed security standards and recommend the DEA consider interim solutions to permit implementation as soon as possible after the Final Rule becomes effective on June 1, 2010.

As the only ePrescribing network with market-based experience, Emdeon through its eRx Network is already demonstrating the achievability of ePrescribing of controlled substances and its potential impact on healthcare. Emdeon is participating in a multi-year research project with the Massachusetts Department of Public Health (MDPH) for ePrescribing of controlled substances. The project began in 2007 and Emdeon believes the lessons learned can assist in developing implementation guidelines for the Final Rule within existing workflows, standards, certifications and technology changes.

"ePrescribing in general, and specifically ePrescribing of controlled substances, can bring several benefits to physicians, pharmacists, patients and the health system as a whole," said George Lazenby, chief executive officer of Emdeon. "Emdeon wants to do everything we can to support nationwide implementation of ePrescribing of controlled substances as soon as possible."

ePrescribing of controlled substances is expected to help overcome the last major barrier preventing certain physicians from ePrescribing as they will no longer have to maintain both paper and electronic workflows. Emdeon believes another benefit of ePrescribing of controlled substances to pharmacies, hospitals and practitioners will be the added level of security for controlled substance prescriptions that come with the new DEA regulations.

Emdeon's comments, which are both supportive and constructive, focus on the provisions that require a secure transmission of electronic prescriptions, including provisions relating to digital signature indicators and digital signatures; signing and transmitting prescriptions; content alteration and two-factor authentication. Emdeon's comments note that it believes the industry will take a significant amount of time to adopt and implement formal standards that address all parts of the Final Rule and suggests the DEA consider interim guidelines to support adoption variances. Emdeon believes such variances would permit quicker adoption while allowing the industry sufficient time to develop and implement long-term infrastructure to meet the minimum requirements of the Interim Final Rule.

"Security and data integrity are the most important factors driving the future success of ePrescribing of controlled substances," said Rick Sage, Emdeon's vice president of clinical services and the manager of Emdeon's participation in the MDPH research project. "Working in conjunction with our partners in the MDPH project, we successfully implemented a workable solution for electronic data transmission security. While the Interim Final Rule mandates some specific requirements that differ from the MDPH project, there are certainly enough similarities that will enable Emdeon to readily assist our partners in implementing and complying with the Final Rule."

Emdeon estimates only approximately 18% of all prescriptions are currently transmitted electronically. According to the Centers for Medicare and Medicaid Services, adoption of ePrescribing can enable improvements in patient safety, quality of care and cost effectiveness. ePrescribing can reduce the need to retype medication and dosage information, helps to eliminate the need for interpretation of prescriber handwriting and potentially reduces the amount of labor required to approve and fill any given prescription.

Emdeon's secure and interoperable network is the largest financial and administrative healthcare information exchange in the nation. Clinical exchange volumes among Emdeon's suite of solutions are increasing with a current annual run rate of 100 million ePrescriptions and 30 million clinical messages per year. In total, Emdeon currently facilitates over 5 billion healthcare information exchanges each year through its network which reaches approximately 500,000 physicians, 81,000 dentists, 55,000 pharmacies, 5,000 hospitals and 1,200 payers.

About Emdeon

Emdeon is a leading provider of revenue and payment cycle management solutions, connecting payers, providers and patients in the U.S. healthcare system. Emdeon's product and service offerings integrate and automate key business and administrative functions of its payer and provider customers throughout the patient encounter. Through the use of Emdeon's comprehensive suite of products and services, which are designed to easily integrate with existing technology infrastructures, its customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle process. For more information, visit

Statements made in this press release that express Emdeon's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements, which Emdeon intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements often include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. Forward-looking statements may include information concerning Emdeon's possible or assumed future results of operations, including descriptions of Emdeon's revenues, profitability and outlook and its overall business strategy. You should not place undue reliance on these statements because they are subject to numerous uncertainties and factors relating to Emdeon's operations and business environment, all of which are difficult to predict and many of which are beyond Emdeon's control. Although Emdeon believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect Emdeon's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements, including the risks discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections and elsewhere in Emdeon's Annual Report of Form 10-K for the year ended December 31, 2009, as well as Emdeon's periodic and other reports, filed with the Securities and Exchange Commission.

You should keep in mind that any forward-looking statement made by Emdeon herein, or elsewhere, speaks only as of the date on which made. Emdeon expressly disclaims any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in Emdeon's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SOURCE Emdeon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Emdeon to Present at the Piper Jaffray Annual Health Care Conference
2. Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality
3. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
6. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
7. Task Force Recommends Screening for Hearing Loss in All Newborns
8. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
9. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
10. CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
11. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
Post Your Comments:
(Date:12/1/2015)... --> --> ... by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic ... Analysis - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 40,281.6 Million in 2015, at ... Browse 37 market data T ...
(Date:12/1/2015)... , Dec. 1, 2015 Assurex ... its GeneSight® Psychotropic test giving healthcare providers an expanded ... decisions for patients suffering from depression, anxiety, bipolar ... behavioral health conditions. i . ... --> With the addition of two new ...
(Date:12/1/2015)... , Dec. 1, 2015  Six months of adjunctive ... with type 1 diabetes, according to new research from ... However, it may have a beneficial effect on measures of ... current issue of the Journal of the American Medical ... examining the effect of metformin on overweight and obese adolescents ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Dr. Paul ... Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single Physician ... the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in ... whopping one in three aged 18 to 25 is inked). As tattoos transition to ... In fact, RealSelf , the world’s largest community for learning and sharing information ...
(Date:12/1/2015)... ... , ... The importance of volumetric breast density assessment for ... abstracts accepted for presentation here, at the 101st Annual Radiology Society of North ... of Volpara Solutions’ quantitative breast imaging software tools for providing breast imaging and ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus ... imaging results enhancements at the Radiological Society of North America (RSNA) 2015 annual ...
Breaking Medicine News(10 mins):